National and Kapodistrian University of Athens
Μελέτη της έκφρασης miRNAs που ρυθμίζουν την γονιδιακή έκφραση αποπτωτικών γονιδίων της οικογένειας BCL2, στον καρκίνο του μαστού: αξιολόγηση της διαφοροδιαγνωστικής προβλεπτικής και προγνωστικής τους αξίας
Abstract
dc:descriptionBreast cancer remains the most frequently diagnosed malignancy and the leading cause of cancer death in the female population, accounting for 25% of all new cancer cases and 15% of all cancer deaths, worldwide. It has been estimated that, approximately, 1 in 8 women will develop malignant neoplasia of the mammary gland in their lifetime. One of the main features of disease is the intrinsic molecular heterogeneity, is partially responsible for the existing limitations in the development of therapeutic strategies. The choice of treatment regimen is entirely based on the histopathological analysis and the gene expression profiling of tumors. Indeed, the synthesis of the immunoexpression of certain biomarkers recently contributed to breast cancer classification at different molecular subtypes defined as luminal A, luminal B, HER2-overexpression, and basal-like/TNBCs. Each molecular subtype of mammary carcinomas is associated with specific carcinogenic pathways, exhibiting variations in biological behavior, metastatic cell dynamics, and by extension, in patient response to administered regimens. Hence, the molecular and histological classification of tumors has been claimed to be crucial for the determination of an appropriate therapeutic approach. Therefore, the identification of new biomolecules is necessary and vital for breast cancer patients. Particularly, when their expression will be correlated with molecular subtypes and clinicopathological variables, or will play a regulatory role in factors that contribute to tumorigenesis and further stages of breast disease.However, in the past decade, the emergence of miRNAs has occasioned new opportunities in cancer investigation and treatment. Interestingly, it has been suggested that miRNAs might be valuable as breast cancer biomarkers because their expression pattern seems to be associated with the clinicopathological features of this disease. Hence, identifying aberrations in miRNA expression might lead to significant improvement in prognosis, diagnosis, and the monitoring of breast malignancies. Moreover, miRNAs are candidate biomolecules for targeted molecular therapy in breast cancer and various approaches to manipulating their expression are under development.One of the mechanisms by which miRNAs affect tumor growth is by regulating the proteins that are involved in the apoptotic process, and named as apoptomiRs. The deregulation of the apoptotic mechanism constitutes a transient stage, allowing genetically unstable cells to survive and accumulate further mutations that eventually lead to tumorigenesis. Several members of the BCL2 family were found to be regulatory targets of apoptomiRs. Elevated expression of anti-apoptotic genes or, respectively, reduced expression of pre-apoptotic genes of the BCL2 family is associated with the pathogenesis and progression of breast cancer, as well as, with the response of tumors to the respective therapeutic approach. Furthermore, a plethora of data recognizes miRNAs as regulators that directly or indirectly target BCL2 family members, as well as downstream targets in breast cancer. In the present Ph.D. Thesis, the expression and the clinical value of miR-29b-3p, miR-128-1-5p, miR-331-3p, miR-365a-3p, miR-195-5p and miR-497-5p, was investigated for the first time. These micromolecules regulate the expression of apoptotic genes of the BCL2 family, in breast cancer. The main objectives of the Ph.D. Thesis were the development of sensitive methodologies for the expression analysis of the examined miRNAs that post-transcriptionally regulate apoptotic genes of BCL2 family, as well as the evaluation of their differential diagnosis, predictive and prognostic significance in breast cancer.In order to accomplish these objectives, the collection of biological material was initially carried out in accordance with the ethical principles governing medical and clinical research. Specifically, a statistically significant number of 210 histological samples originated from 140 malignant and 70 benign breast tumors. Tissue processing included homogenization, isolation of total RNA, quality control of the purity and integrity of RNA, and determination of RNA concentration in each histological specimen. Thereafter, the polyadenylation of total RNA was carried out, followed by the reverse transcription reaction, resulting in cDNA of all different miRNAs. Subsequently, the expression of miR-29b-3p, miR-128-1-5p, miR-331-3p, miR-365a-3p, miR-195-5p and miR-497-5p, as well as the SNORD48 reference gene that is also known as RNU48, was analyzed. Specific primers were designed for the expression analysis of the aforementioned biomolecules, followed by the development and optimization of the qRT-PCR protocol using the SYBR Green I dye and finally, their expression levels were determined by applying the 2-ΔCTT relative quantification method. The present study was completed by the creation of a detailed database with a complete record of patients' clinicopathological parameters and their postoperative course, and afterwards, by conducting extensive biostatistical analysis in order to assess the clinical value of the tested miRNAs.The study of miR-29b, which contributes to the regulation of the anti-apoptotic genes BCL2, BCLW and MCL1, revealed that its expression could be detected in all breast tumor groups without any changes between the cancerous and benign breast tissue specimens. Consequently, the expression of miR-29b has no significant diagnostic value for the distinction between malignant and benign breast tumors. However, the expression of miR-29b differentiated between lobular and ductal breast carcinomas, showing a significant decrease (P=0.010) in the ductal. One more finding was obtained by correlating the expression of miR-29b with staging of the primary tumor size (P=0.035). The miR-29b expression levels gradually declined as T staging progressed, demonstrating in parallel the propensity to negatively correlate with tumor size. Moreover, the correlation of miR-29b expression with the ER status of the analyzed samples, revealing significant overexpression of miR-29b in the ER-positive ones (P=0.021). Furthermore, miR-29b overexpression was correlated with longer DFS (P=0.010) in Kaplan-Meier analysis and lower risk of relapse in univariate Cox regression model (HR= 0.35, 95% CI: 0.15 – 0.81; P=0.014). Taking into account the above findings, miR-29b expression levels constitute a promising biomarker of favorable prognosis for patients with invasive ductal breast carcinoma and imply that its expression status might be affected by the histological origin of breast malignancy.miR-128 is a post-transcriptional regulator of pro-apoptotic BAX gene According to our data, the expression of miR-128 was more elevated in cancerous samples compared to those observed in benign ones (P=0.004). Additionally, the ROC analysis confirmed the diagnostic value of the miR-128 expression levels in distinguishing malignant from benign breast tumors (AUC=0.642; 95%CI=0.552-0.732; P=0.004). Ιn view of the fact that miR-128-positive patients are correlated with longer DFS (P=0.010) and OS (P=0.006), as well as, with lower risk of relapse [DFS-univariate Cox regression analysis (HR= 0.43, 95% CI: 0.218 – 0.833; P=0.013), DFS- multivariate (HR=0.39, 95% CI: 0.180 – 0.861; P=0.020)] or death due to the disease(HR= 0.36, 95% CI: 0.164 – 0.769; P = 0.009), the expression of miR-128 could be considered as a promising independent favorable prognostic marker in breast cancer.One of the miRNAs associated with the regulation of the pro-apoptotic ΒΑΧ and its expression status in breast cancer was firstly studied herein, is miR-331. According to the statistical evaluation of our data, it was revealed that miR-331 was significantly upregulated (P=0.026) in malignant specimens in comparison to their benign counterparts. In addition, ROC curve analysis showed that miR-331 levels had the potential to discriminate between samples of malignant and benign phenotype (AUC:0.597±0.044, 95% CI 0.511–0.683, P=0.026). Τhe expression of miR-331 was correlated only with the histological subtype, uncovering its significantly downregulation in lobular carcinomas (P=0.026). By virtue of the lack of any other correlation, miR-331 demonstrates no prognostic value for breast cancer.Τhe expression analysis of miR-365, which target the anti-apoptotic BCL2, revealed the significantly decreased levels of miR-365 in benign tumors (P<0.001). Moreover, our ROC curve analysis added diagnostic value to the above observation indicating that miR-365 levels had discriminatory power in distinguishing cancerous from benign breast lesions (AUC: 0.704, 95% CI 0.629–0.779, P<0.001). Regarding the clinicopathological parameters, a statistically significant lower expression of the miR‐365 was observed in the ductal (P=0.003) and the triple negative (TNBC) (P<0.001) by comparison with lobular carcinomas and the other molecular subtypes. Furthermore, miR‐365 levels were positively correlated with ER (P<0.001) and PR (P<0.007) staining, suggesting its possible contribution as an indication of good prognosis for patients. However, the lack of significant correlation of miR-365 levels with DFS and OS did not further enhance its clinical value in breast cancer.Finally, for first time, the expression of the miR-195/497 cluster, both miRNAs are considered to be direct regulators of the BCL2 gene, was investigated in malignant and benign breast samples. Significantly lower expression levels of miR-195/497 cluster were observed in cancerous compared to benign specimens (miR-195: P=0.015, miR-497: P<0.001). Additionally, their differential diagnostic value was confirmed for patients with breast tumors. Specifically, miR‐195/497 levels showed the ability to accurately discriminate between malignant and benign specimens, based on ROC curve analysis [(miR-195: AUC:0.605, 95% CI 0.525–0.685, P=0.015), (miR-497: AUC:0.848, 95%CI=0.792-0.905, P<0.001)]. Αs regards the histological and molecular subtypes of the breast, only miR-195 revealed significant correlation (P<0.001), detecting the lower expression in both ductal and TNBC carcinomas. Moreover, increased levels of miR-195 were correlated with the group of ER-positive cancer samples (P=0.002). In the case of miR-497, statistically significant negative correlation was observed between the expression of miR-497 and the histological degree of differentiation (Grade I-III) (P=0.031), the staging of the primary tumor size (P=0.013) as well as, the expression of mitotic index Ki67 (P=0.026). The prognostic value of miR-497 was enhanced by survival analyses, indicating that decreased miR-497 levels significantly associated with sorter DFS of breast cancer patients (P=0.028) in Kaplan-Meier analysis and with a twofold risk of relapse in univariate Cox regression analysis (HR= 2.282, 95% CI:1.069 – 4.869; P=0.033).Ιn conclusion, in the present Ph.D. Thesis, 210 tissue specimens from malignant and benign breast tumors were collected. Samples were processed by developing methodologies to determine the tested miRNAs that regulate apoptotic genes of BCL2 family. Thereafter, the expression levels of the examined biomolecules were correlated with the clinicopathological features and post-operative status of patients, by comprehensive statistical analysis. Οur findings revealed the significant clinical value in the majority of examined miRNAs for the differential diagnosis and prognosis in breast cancer. Interestingly, the comparative study of findings among miRNAs (miR-29b, miR-365 and miR-195) regulating anti-apoptotic genes revealed that their overexpression was correlated with lobular adenocarcinomas. This observation seems to be of special clinical and investigational value, as it might possibly generate a hypothesis that needs to be tested regarding the effect of the histological origin of breast malignancy on the miRNAs that target anti-apoptotic genes and specifically BCL2. Furthermore, the association of miR-365 and miR-195 expression levels with molecular subtypes of breast cancer, might provide additional information on the therapeutic approach of TNBC adenocarcinomas, whose patients lack the options of targeted and hormone therapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papachristopoulou, Georgia
- Παπαχριστοπούλου, Γεωργία
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45736